干扰素联合肝动脉化疗栓塞和门静脉化疗对预防肝癌术后复发的临床意义分析  

Clinical significance of interferon combined with hepatic arterial chemoembolization and portal vein chemotherapy in preventing postoperative recurrence of liver cancer

作　　者：赵晨晨 杨方[1] 王伟[1] ZHAO Chen-chen;YANG Fang;WANG Wei(Third Department of Liver Diseases,Shenyang Sixth People’s Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市第六人民医院肝病三科,110000

出　　处：《中国现代药物应用》2022年第3期150-152,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究干扰素联合肝动脉化疗栓塞和门静脉化疗对预防肝癌术后复发的临床意义。方法60例肝癌患者,随机分为对照组与试验组,各30例。对照组采取肝动脉化疗栓塞和门静脉化疗方法,试验组在对照组治疗基础上联合干扰素治疗。比较两组临床指标、治疗后6个月内复发率及远处转移率。结果试验组CD3^(+)(68.02±2.55)%、CD4^(+)(40.50±1.12)%、CD8^(+)(27.32±1.13)%、CD4^(+)/CD8^(+)(1.54±0.11)均优于对照组的(49.86±2.53)%、(16.45±1.11)%、(31.18±1.13)%、(1.45±0.12),差异有统计学意义(P<0.05)。治疗后6个月内,试验组复发率及远处转移率分别为6.67%、3.33%,均低于对照组的26.67%、20.00%,差异均有统计学意义(P<0.05)。结论采取干扰素联合肝动脉化疗栓塞和门静脉化疗预防肝癌患者术后复发效果显著,值得推广。Objective To investigate the clinical significance of interferon combined with hepatic arterial chemoembolization and portal vein chemotherapy in preventing postoperative recurrence of liver cancer.Methods A total of 60 patients with liver cancer were randomly divided into control group and test group,with 30 cases in each group.The control group took hepatic arterial chemoembolization and portal vein chemotherapy,and the test group was combined with interferon therapy on the basis of the control group.The clinical indicators,recurrence rate and distant metastasis rate within 6 months after treatment were compared between the two groups.Results The CD3^(+)(68.02±2.55)%,CD4^(+)(40.50±1.12)%,CD8^(+)(27.32±1.13)%,CD4^(+)/CD8^(+)(1.54±0.11)in the test group were better than(49.86±2.53)%,(16.45±1.11)%,(31.18±1.13)%,(1.45±0.12)in the control group,and the difference was statistically significant(P<0.05).Within 6 months after treatment,the recurrence rate and distant metastasis rate of the test group were 6.67%and 3.33%,which were lower than 26.67%and 20.00%of the control group,and the differences were statistically significant(P<0.05).Conclusion Interferon combined with hepatic arterial chemoembolization and portal vein chemoembolization is effective in preventing postoperative recurrence of liver cancer patients,and is worthy of promotion.

关 键 词：干扰素 肝动脉化疗栓塞 门静脉化疗 复发 

分 类 号：R735.7[医药卫生—肿瘤]